Search Clinical Trials
Sponsor Condition of Interest |
---|
SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding
University of Wisconsin, Madison
COVID-19
SARS-CoV 2
Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will
be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel
coronavirus is easily transmissable through close contact between individuals, especially
during aerosol-generating procedures... expand
Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedures such as intubation of patients. The intervention proposed in this study (nasal and oral decontamination with povidone-iodine and chlorhexidine, respectively) presents an opportunity for a safe, effective, and feasible treatment to decontaminate the primary entry points for SARS-CoV-2. As such, the intervention to be studied in this project may protect healthcare and other essential workers by preventing transmission of SARS-CoV-2 from patients to healthcare workers, as well as the general public to essential worker,. and thus reducing the incidence of COVID-19 in these workers. Type: Interventional Start Date: Jul 2020 |
Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related...
Northwell Health
Covid-19 (SARS-CoV-2)
Descriptive report of the Northwell CROWN program for ambulatory treatment of COVID-19
(SARS-CoV-2) patients with moderate to high risk features expand
Descriptive report of the Northwell CROWN program for ambulatory treatment of COVID-19 (SARS-CoV-2) patients with moderate to high risk features Type: Observational Start Date: Apr 2020 |
A Study of Immune Responses to the Virus That Causes COVID-19
COVID-19 Prevention Network
SARS-CoV-2
COVID-19
The purpose of this study is to learn more about the acute response to infection with and
recovery from the virus called severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the
disease called COVID-19.
The information... expand
The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study can be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines, other prevention strategies, and treatments. Type: Observational Start Date: Jul 2020 |
Acquiring Convalescent Specimens for COVID-19 Antibodies
Columbia University
COVID-19
Coronavirus Infection
Corona Virus Infection
Blood samples from participants who have recovered from COVID-19 infection will be
obtained and studied. The goal of the research is to identify antibodies that have been
generated by the patient to fight the COVID-19 infection. By identifying the most
effective antibodies, scientists can make specific... expand
Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify antibodies that have been generated by the patient to fight the COVID-19 infection. By identifying the most effective antibodies, scientists can make specific antibodies to use to prevent future coronavirus outbreaks or to treat patients with severe disease. Type: Observational Start Date: Mar 2020 |
Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)
Lumos Diagnostics
SARS-CoV-2
Covid19
Prospective study that will evaluate the clinical agreement of the CoviDx™ Self test
compared to SARS-CoV-2 RT-PCR. expand
Prospective study that will evaluate the clinical agreement of the CoviDx™ Self test compared to SARS-CoV-2 RT-PCR. Type: Observational Start Date: May 2022 |
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
Cytokind, Inc.
Covid19
Corona Virus Infection
Autoimmune Diseases
Coagulation Disorder, Blood
The purpose of this study to evaluate the translational application of the safe and
effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk
COVID-19 patients in an effort to improve their immune and hemostatic imbalance to
increase survival and improve outcomes. expand
The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and hemostatic imbalance to increase survival and improve outcomes. Type: Interventional Start Date: May 2021 |
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Eli Lilly and Company
COVID-19
The purpose of this study is to measure how well monoclonal antibodies work, either alone
or in combination, against the virus that causes COVID-19. Study drug(s) will be given to
participants with early symptoms of COVID-19. Samples will be taken from the back of the
nose to determine how much virus... expand
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone. Type: Interventional Start Date: Oct 2020 |
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
Gregory Yanik
COVID
Sars-CoV2
COVID-19
Acute Respiratory Distress Syndrome
This clinical trial will enroll participants that have pneumonia caused by the COVID-19
virus. During the study patients will receive 7 to up to 14 days of defibrotide. After
completing the treatment, participants will have 30 day follow-up check-up to assess for
adverse events and clinical status.... expand
This clinical trial will enroll participants that have pneumonia caused by the COVID-19 virus. During the study patients will receive 7 to up to 14 days of defibrotide. After completing the treatment, participants will have 30 day follow-up check-up to assess for adverse events and clinical status. This final assessment can be done virtually, by telephone or electronically (email) if the patient cannot be contacted by phone. No in-person visit is required. The hypothesis of this trial is that defibrotide therapy given to patients with severe SARS-CoV2 ARDS will be safe and associated with improved overall survival, within 28 days of therapy initiation. Type: Interventional Start Date: Oct 2020 |
Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19
Stanford University
Coronavirus
The purpose of this study is to test over time immunity to SARS-CoV-2, a recently
identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as
COVID-19. Adults and children diagnosed with COVID-19 as well as controls without
COVID-19 will be invited to participate in this... expand
The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19. Adults and children diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study. Type: Observational Start Date: Apr 2020 |
Pegylated Interferon Lambda Treatment for COVID-19
Raymond Chung
COVID-19
COVID
Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon
Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection. expand
Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection. Type: Interventional Start Date: Jun 2020 |
Will Hydroxychloroquine Impede or Prevent COVID-19
Henry Ford Health System
COVID-19
Coronavirus
Coronavirus Infections
SARS-CoV 2
This is a prospective, multi-site study designed to evaluate whether the use of
hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first
responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE,
Michigan, can prevent the acquisition, symptoms and... expand
This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE, Michigan, can prevent the acquisition, symptoms and clinical COVID-19 infection The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection healthcare workers (HCW) and first responders (FR) (EMS, Fire, Police, bus drivers) in Southeast Michigan. Preventing COVID-19 transmission to HCW, FR, and Detroit Department of Transportation (DDOT) bus drivers is a critical step in preserving the health care and first responder force, the prevention of COVID-19 transmission in health care facilities, with the potential to preserve thousands of lives in addition to sustaining health care systems and civil services both nationally and globally. If efficacious, further studies on the use of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives. Type: Interventional Start Date: Apr 2020 |
Losartan for Patients With COVID-19 Requiring Hospitalization
University of Minnesota
Corona Virus Infection
Acute Respiratory Distress Syndrome
SARS-CoV Infection
This is a multi-center, double-blinded study of COVID-19 infected patients requiring
inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or
hospital discharge. expand
This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge. Type: Interventional Start Date: Apr 2020 |
COPD Circuit Exercise
Texas A&M University
OSA
Covid19
Residual Symptoms of COVID 19
COPD
This study is being done to understand body's response to hybrid home-based and on-site
rehabilitation program utilizing individually tailored exercises throughout a total of 18
sessions with 12 of them occurring onsite, in people with and without chronic respiratory
diseases, such as Chronic Obstructive... expand
This study is being done to understand body's response to hybrid home-based and on-site rehabilitation program utilizing individually tailored exercises throughout a total of 18 sessions with 12 of them occurring onsite, in people with and without chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA) and in individuals recovered from COVID-19. Exercise training programs vary widely for people with COPD, OSA, and during prolonged recovery from COVID infection. This study will help identify if this program is helpful to address muscle loss and fatigue specifically in populations with and without chronic respiratory diseases. Type: Interventional Start Date: Feb 2021 |
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
Tonix Pharmaceuticals, Inc.
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of
intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the
presence and magnitude of DTH reactions. expand
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions. Type: Interventional Start Date: Jan 2022 |
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness
AudibleHealth AI, Inc.
COVID19
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of
an ensemble of software subroutines that interacts with a proprietary database of Signal
Data Signatures (SDS), using Artificial Intelligence/Machine Learning (AI/ML) to analyze
forced cough vocalization signal... expand
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. This study will evaluate the performance of the AudibleHealth Dx in comparison to a standard of care Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) test for the diagnosis of COVID-19. Bidirectional Sanger sequencing will be used to reduce the rate of false negative and false positive results. A secondary purpose of the study will be usability testing of the device for participants and providers. Type: Observational Start Date: Jan 2022 |
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
Pfizer
Healthy
This open-label, single dose study in approximately 5 healthy male and female (of non
childbearing potential only) participants has been designed to characterize mass balance
and further the understanding of human pharmacokinetics, metabolism, and excretion of PF
07304814 administered at a dose of... expand
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of PF 07304814 administered at a dose of 500 mg [14C] PF-07304814 containing approximately 420 nCi [14C] PF-07304814 as a constant-rate, continuous IV infusion over 24 hours Type: Interventional Start Date: Oct 2021 |
Low-Dose Chest CT (LDCT) COVID-19 Study
Kaiser Permanente
Covid19
The goal of our proposed pilot study is to collect low dose CT (LDCT) findings from chest
evaluations of a representative sample of 120 symptomatic Caucasian and African American,
and Hispanic adults (45 each), stratified by presence of acute respiratory distress
syndrome (ARDS) and COVID-19 positivity... expand
The goal of our proposed pilot study is to collect low dose CT (LDCT) findings from chest evaluations of a representative sample of 120 symptomatic Caucasian and African American, and Hispanic adults (45 each), stratified by presence of acute respiratory distress syndrome (ARDS) and COVID-19 positivity or negative PCR screening results. These data will provide us with preliminary data on the type and extent of alveolar remodeling by race and by severity of recent infectious respiratory disease. Findings from our study would will help us to determine if a larger multi-site research application to NHLBI or a similar funding agency might be possible and provide critical preliminary data on variation in LDCT findings by COVID-19 attributable respiratory health, race, and other risk factors (e.g., smoking history, comorbidities, and socioeconomic status). Type: Observational Start Date: Mar 2021 |
A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)
Ampio Pharmaceuticals. Inc.
Covid19
This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients
with prolonged respiratory symptoms due to COVID-19 (Long COVID). expand
This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID). Type: Interventional Start Date: Jul 2021 |
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
EMD Serono Research & Development Institute, Inc.
Coronavirus Disease 2019
The study will evaluate the safety and efficacy of orally-administered M5049 in
Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not
on mechanical ventilation. expand
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation. Type: Interventional Start Date: Jul 2020 |
Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness
University of Texas at Austin
Loneliness
The primary aim of this study is to examine the efficacy of a one-session, hour-long
HIPAA-compliant video platform-based mindfulness + compassion telehealth intervention on
reducing feelings of loneliness during COVID-19 quarantine. Participants (n=120)
currently isolating due to COVID-19 will be... expand
The primary aim of this study is to examine the efficacy of a one-session, hour-long HIPAA-compliant video platform-based mindfulness + compassion telehealth intervention on reducing feelings of loneliness during COVID-19 quarantine. Participants (n=120) currently isolating due to COVID-19 will be randomized to one of three interventions: (a) mindfulness + compassion (MC); (b) mindfulness alone (MO); and (c) waitlist control (WL). The investigators predict that participants in the active intervention groups (mindfulness or mindfulness + compassion) will show a significantly greater reduction in subjective feelings of loneliness at one week follow-up compared to those in the waitlist control group. Additionally, investigators predict that participants in the active intervention groups will show a significantly greater reduction in stress at one week follow-up compared to those in the waitlist control group. Last, investigators predict that participants in the mindfulness + compassion group will show a significantly greater reduction in subjective feelings of loneliness at the 2-week follow-up follow-up relative to those in the mindfulness only group. Type: Interventional Start Date: May 2020 |
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute...
AbbVie
CoronaVirus Induced Disease-2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death
related to COVID-19 infection. The main objective of this study was to evaluate if
ibrutinib is safe and can reduce respiratory... expand
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection. The main objective of this study was to evaluate if ibrutinib is safe and can reduce respiratory failure in participants with COVID-19 infection. Type: Interventional Start Date: Jun 2020 |
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
Alexion Pharmaceuticals, Inc.
COVID-19 Severe Pneumonia
Acute Lung Injury
Acute Respiratory Distress Syndrome
Pneumonia, Viral
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of
ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19)
severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants
were randomly assigned to receive ravulizumab... expand
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants were randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the participants) or BSC alone (1/3 of the participants). BSC consisted of medical treatment and/or medical interventions per routine hospital practice. Type: Interventional Start Date: May 2020 |
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Celularity Incorporated
Coronavirus
Coronavirus Infection
Severe Acute Respiratory Syndrome Coronavirus 2
Pneumonia
Pneumonia, Viral
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an
immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+
cells and culture-expanded, in patients with moderate COVID-19 disease. expand
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease. Type: Interventional Start Date: May 2020 |
COVID-19 Community Research Partnership
Wake Forest University Health Sciences
Coronavirus
COVID
The purpose of this research is to collect information about the North Carolina
community's coronavirus exposures, symptoms, and health care visits due to the virus.
Participation in this study will involve completing a daily questionnaire which covers
participants coronavirus illness history or symptoms,... expand
The purpose of this research is to collect information about the North Carolina community's coronavirus exposures, symptoms, and health care visits due to the virus. Participation in this study will involve completing a daily questionnaire which covers participants coronavirus illness history or symptoms, health care seeking behaviors and treatments, contact with other sick people, and for health care workers, their use of personal protective equipment. Type: Observational Start Date: Apr 2020 |
COVID-19 in Patients With HIV
University of Missouri-Columbia
HIV/AIDS
COVID-19
SARS-CoV-2
Currently, limited data is available about patients with HIV in the context of the
COVID-19 pandemic. People with HIV who have not achieved viral suppression through
antiretroviral treatment may have a compromised immune system that leaves them vulnerable
to infections and disease progression. However,... expand
Currently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. However, little is known about the presentation and clinical outcomes of patients with HIV and SARS-CoV-2. Our aim is to characterize the clinical presentation and disease course of COVID-19 in patients with HIV. Type: Observational [Patient Registry] Start Date: Apr 2020 |
- Previous
- Next